On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

  • XPhyto partners with AGORA t to grow its brand and overall market share
  • The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021
  • AGORA is known for its online marketing, conferences, broadcasting and investor relations services
  • Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp (“AGORA”) that dates back to December 1, 2020. The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 with respect to the various applicable securities legislation. With this move, AGORA now holds 20,549 common shares of XPhyto, equivalent to 0.03% of the issued and outstanding common shares (https://ibn.fm/GVoHm). AGORA is known for its online marketing, conferences, broadcasting and investor relations services for the global market. With its online community, AGORA is able to help investors and small companies to not only discuss but also discover small cap stocks and investment opportunities (https://ibn.fm/BgDHx). Its client list is constantly growing and is currently made up of companies such CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others (https://ibn.fm/cuUyv). XPhyto plans on capitalizing on the experience that AGORA has by working with the other clients and leveraging on this to grow its brand and overall market share. XPhyto is a life sciences technology accelerator, focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its biggest achievement so far has been its rapid COVID-19 PCR test kit that reduces test turnaround times to less than 30 minutes (https://ibn.fm/KELop). The company has operations in Europe and North America, with an operational focus in Germany. This partnership with AGORA has the potential to push the XPhyto brand even further, allowing it to appeal to more customers and fulfil its agenda for growth and commercialization for the European market. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

From Our Blog

Torr Metals Inc. (TSX.V: TMET) Set to Capitalize on Green Energy’s Rising Demand for Copper

April 26, 2024

Global warming has become an undeniable force around the globe, with news of widespread droughts, record temperatures, forest fires, and ravaged agricultural harvests increasing in frequency. In response, global leaders came together during 2021’s COP26 event in Glasgow to propose a global Net Zero initiative, aimed towards achieving a balance between global greenhouse gas (“GHG”) […]

Rotate your device 90° to view site.